ClinicalTrials.gg
Not yet recruitingNCT07938281Updated Nov 16, 2026

Artificial Intelligence-enabled Management of Atrial Fibrillation(ABLE-AF Trial)

An interventional study of ECG Analysis Software AiTiALVDD and ECG Analysis Software AiTiALVSD in AF - Atrial Fibrillation, sponsored by Korea University Anam Hospital. Not yet recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Korea University Anam Hospital · Not applicable, Interventional, and Diagnostic

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,006
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 208 studies in Atrial Fibrillation with a site in Korea, Republic of — 60 open to participants now, 68 under way, 2 of them phase 3. Atrial Fibrillation · Korea, Republic of.

Planned enrollment
32nd of 143
1,006 · median 300
Started
2026
with 16 others
No phase
90 of 208
35 open now
Primary completion
2029-12
later than 55 of 67 live
Registered
207th of 208
by date
Lead sponsor
7 of 208
Korea University Anam Hospital

Among the 208 studies in Atrial Fibrillation with a site in Korea, Republic of, this one is the 32nd largest by planned enrollment of the 143 interventional ones that give a count, is one of 17 that started in 2026, is one of 90 with no phase, reaches primary completion later than 55 of the 67 other live ones, and was the 207th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

60 of the 208 studies in Atrial Fibrillation with a site in Korea, Republic of are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 208 studies in Atrial Fibrillation with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common type of irregular heartbeat in adults. People with AF may also have other heart problems, including reduced heart pumping function or diseases affecting the heart muscle or heart valves. Identifying these problems early is important because the condition of the heart can affect treatment decisions and long-term care.

An ultrasound examination of the heart, called transthoracic echocardiography (TTE) or an echocardiogram, is commonly used to check how well the heart pumps blood and to look for structural problems, such as heart valve disease. However, an echocardiogram requires special equipment and trained healthcare professionals to perform and interpret the examination. Because of these requirements, it may not always be available when needed. This can be particularly challenging in situations where heart function needs to be evaluated quickly, such as when a patient with AF has a very fast heart rate. Delays may also occur in outpatient settings because of limited availability of echocardiography.

Artificial intelligence (AI) technology may provide an additional way to identify patients who are more likely to have heart problems and who may benefit from further evaluation. A standard 12-lead electrocardiogram (ECG) is a simple and widely available test that records the electrical activity of the heart. AI-based computer programs can analyze information contained in an ECG that may not be easily recognized through routine interpretation.

This study will use two AI-based ECG programs, called AiTiALVSD and AiTiALVDD. AiTiALVSD analyzes a standard 12-lead ECG to identify patients who may have reduced heart pumping function. Previous studies have evaluated this program in different clinical settings, including patients with AF and a fast heart rate.

AiTiALVDD analyzes the ECG for signs that may be associated with difficulty in the heart relaxing and filling with blood. Problems with heart relaxation and filling may occur in several types of heart disease, including heart valve disease, abnormal thickening of the heart muscle, heart disease related to high blood pressure, diseases affecting the heart muscle, and coronary artery disease. Importantly, some patients may have these conditions even when the heart's overall pumping function is normal. Therefore, evaluating only pumping function may not identify all patients who have important underlying heart disease.

By using AiTiALVSD and AiTiALVDD together, this study aims to evaluate a broader AI-based approach to identifying heart problems in patients with AF. AiTiALVSD may help identify patients who are more likely to have reduced heart pumping function, while AiTiALVDD may provide additional information about possible problems with heart relaxation and filling. A high-risk result from AiTiALVDD may serve as a signal that further heart evaluation should be considered, including evaluation for significant heart valve disease or other underlying structural heart conditions.

The purpose of this study is to evaluate whether using these two AI-based ECG programs together can help identify patients with AF who may have previously unrecognized problems with heart function or underlying heart disease. Patients identified by the AI analysis as being at higher risk may receive further evaluation as appropriate to determine whether additional heart disease is present.

The study will also evaluate the clinical usefulness of this AI-based ECG approach in routine care. The goal is not to replace an echocardiogram or a physician's clinical assessment. Instead, AI-based ECG analysis may serve as an additional screening tool to help healthcare professionals identify patients who may benefit from further cardiac testing.

By using information from a routinely performed ECG, this approach may help support earlier and more efficient evaluation of heart function and underlying heart disease in patients with AF. The results of this study will help determine whether combining AiTiALVSD and AiTiALVDD can provide useful information for deciding which patients may need additional cardiac evaluation and whether this approach can improve the process of identifying clinically important heart conditions.

03

Conditions studied

  • AF - Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Atrial fibrillation (AF) with rapid ventricular response confirmed on the day of screening or within 90 days before screening.
  • Rapid ventricular response is defined as (i) a ventricular rate ≥110 bpm or (ii) a ventricular rate ≥100 bpm with related symptoms.
  • AF can be confirmed by any guideline-accepted electrocardiographic () method, including 12-lead ECG, Holter ECG, or single-lead ECG (e.g., patch ECG or smartwatch).
  • AF must be documented for at least 10 seconds on a 12-lead ECG or at least 30 seconds on Holter or single-lead ECG.

Exclusion criteria

Exclusion Criteria

  • (LV EF) assessed by transthoracic echocardiography (TTE) within the past 6 months.
  • If TTE was performed at another institution within the past 6 months, this exclusion criterion applies only when objective imaging data confirming LV EF are available.
  • Hemodynamically unstable patients requiring immediate direct current cardioversion.
  • Acute decompensated heart failure requiring immediate hospitalization.
  • to AF pharmacotherapy (e.g., pregnancy).
  • Hospitalization for acute myocardial infarction (STEMI or NSTEMI) within the past 3 months.
  • 12-lead not available in a format analyzable by the AI model.
  • Individuals aged 18 years or younger.
  • Diagnosis of severe valvular disease (e.g., severe aortic stenosis).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
1,006 participants (estimated)

Study arms

  • Active comparator
    Conventional Treatment

    Pharmacologic treatment will be initiated after TTE is performed, in accordance with guideline recommendations. * Rate control: In accordance with guideline recommendations, the choice of rate-control agent may be based on LV EF (≤40% or not). However, in patients requiring acute rate control, agents that can be used regardless of LV EF (beta-blocker, digoxin) may be used without prior TTE.1 * Rhythm control: In accordance with guideline recommendations, antiarrhythmic drug therapy may be initiated after assessment of LV EF and structural heart disease. Because oral amiodarone is not recommended as first-line therapy when LV EF \>40%, it may not be used preferentially without information on LV EF. 1,2 * When underlying heart failure is suspected, guideline-recommended pharmacotherapy will also be administered; however, when acute or congestive heart failure is suspected, agents that can be used without LV EF information (e.g., diuretics) may be initiated.

    Device: ECG Analysis Software AiTiALVSD

  • Experimental
    AI-Guided Treatment

    Guideline-directed AF pharmacotherapy may be initiated based on the AI-predicted LV EF obtained on the day of enrollment. Because patients with AF undergo a 12-lead ECG for clinical purposes, in the investigational group the AI-predicted LV EF becomes available immediately once the AI-enabled 12-lead ECG is performed. * TTE may also be performed in the investigational group, in accordance with guideline recommendations, to assess structural heart disease and left atrial substrate, and treatment may be modified based on the TTE results. * Rate control: The choice of agent may be based on the AI-predicted LV EF.1 * Rhythm control: If the AI-predicted LV EF is \>40%, there is no history of coronary artery disease, and there is no suspicion of moderate-to-severe valvular disease (e.g., no murmur), a Class IC antiarrhythmic drug (propafenone, flecainide, etc.) may be used in accordance with guideline recommendations. If the AI-predicted LV EF is ≤40%, oral amiodarone may be administered.1,2

    Device: ECG Analysis Software AiTiALVDD

Interventions

  • DeviceECG Analysis Software AiTiALVDD

    * Classification code (grade): B2ABXA1(3) * Mechanism of action: When biosignal data (raw 12-lead ECG data) measured by an ECG device are automatically transmitted or uploaded, an artificial intelligence algorithm displays a score and risk level for the likelihood of left ventricular diastolic dysfunction, for use as a diagnostic aid. Analyzed ECGs can be stored in HL7 aECG XML, JPG, or DICOM format.

  • DeviceECG Analysis Software AiTiALVSD

    * Classification code (grade): E01020.01(2) * Mechanism of action: When biosignal data (12-lead ECG) from an ECG device are automatically transmitted, or uploaded by the user, this software applies an artificial intelligence algorithm to the ECG data to predict the likelihood of left ventricular systolic dysfunction and displays the analysis results on a web-based screen.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events (MACE), a composite outcome

    Major adverse cardiovascular events (MACE) will be assessed as a composite outcome comprising all-cause death, cardiovascular death, stroke (ischemic or hemorrhagic), acute coronary syndrome, and cardiovascular hospitalization. The outcome will be reported as the number of participants experiencing at least one of these events during the follow-up period. Participants experiencing multiple component events will be counted only once in the composite outcome.

    Time frame: 1year

Secondary outcomes

  1. Number of Participants with All-Cause Death

    The number of participants who die from any cause during the follow-up period will be assessed. Each participant will be counted only once. Unit of Measure - Number of participants

    Time frame: 1year

  2. Number of Participants with Stroke (Ischemic or Hemorrhagic)

    The number of participants experiencing at least one ischemic or hemorrhagic stroke during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of stroke events. Unit of measure - number of participants

    Time frame: 1year

  3. Number of Participants with Acute Myocardial Infarction

    The number of participants experiencing at least one acute myocardial infarction during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of events. Unit of Measure- Number of participants

    Time frame: 1year

  4. Number of Participants Hospitalized for Heart Failure

    The number of participants experiencing at least one hospitalization for heart failure during the follow-up period will be assessed. Each participant will be counted only once, regardless of the number of hospitalizations. Unit of Measure- Number of participants

    Time frame: 1year

  5. Number of Participants with an Emergency Room Visit or Hospitalization for Cardiovascular Causes

    The number of participants experiencing at least one emergency room (ER) visit or hospitalization for cardiovascular causes during the follow-up period will be assessed. Participants experiencing both an ER visit and hospitalization for cardiovascular causes will be counted only once. Unit of Measure- Number of participants

    Time frame: 1year

  6. Percentage of Participants Achieving Atrial Fibrillation Rate Control

    Atrial fibrillation (AF) rate control will be assessed as the percentage of participants achieving a heart rate of less than 110 beats per minute (bpm) during the specified assessment period. Unit of Measure: Percentage of participants

    Time frame: 1year

  7. Time to Achievement of Atrial Fibrillation Rate Control

    Time to AF rate control will be measured in days from the protocol-defined starting point to the first documented achievement of a heart rate of less than 110 bpm. Unit of Measure: Days

    Time frame: 1year

  8. Time to Initiation of Oral Antiarrhythmic Drug Therapy

    Time to initiation of oral antiarrhythmic drug therapy will be measured in days from the protocol-defined starting point to the first documented initiation of oral antiarrhythmic drug therapy. Unit of Measure: Days

    Time frame: 1year

  9. Time to Atrial Fibrillation Catheter Ablation

    Time to atrial fibrillation (AF) catheter ablation will be measured in days from the protocol-defined starting point to the date of the first AF catheter ablation procedure. Unit of Measure: Days

    Time frame: 1year

  10. Time to Restoration of Sinus Rhythm

    Time to restoration of sinus rhythm will be measured in days from the protocol-defined starting point to the first documented restoration of sinus rhythm. Unit of Measure: Days

    Time frame: 1year

  11. AUC for LV Systolic Dysfunction

    The predictive performance of the artificial intelligence (AI) model for identifying left ventricular (LV) systolic dysfunction will be assessed using the area under the receiver operating characteristic curve (AUC). AUC values range from 0 to 1, with higher values indicating better discrimination. The AUC of the AI model will be compared with that of N-terminal pro-B-type natriuretic peptide (NT-proBNP).

    Time frame: 1year

  12. Sensitivity for LV Systolic Dysfunction

    Sensitivity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants with reference-standard-confirmed LV systolic dysfunction who are correctly identified by the AI model. Values range from 0% to 100%, with higher values indicating better sensitivity.

    Time frame: 1year

  13. Specificity for LV Systolic Dysfunction

    Specificity of the AI model for identifying LV systolic dysfunction will be calculated as the percentage of participants without reference-standard-confirmed LV systolic dysfunction who are correctly identified as negative by the AI model. Values range from 0% to 100%, with higher values indicating better specificity.

    Time frame: 1year

  14. Positive Predictive Value

    Positive predictive value (PPV) will be calculated as the percentage of participants with a positive AI prediction for LV systolic dysfunction who have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater positive predictive value.

    Time frame: 1year

  15. Negative Predictive Value

    Negative predictive value (NPV) will be calculated as the percentage of participants with a negative AI prediction for LV systolic dysfunction who do not have reference-standard-confirmed LV systolic dysfunction. Values range from 0% to 100%, with higher values indicating greater negative predictive value.

    Time frame: 1year

  16. Atrial Fibrillation Burden at 1 Year Assessed by 3-Day Holter Electrocardiography

    Atrial fibrillation (AF) burden at 1 year will be assessed using 3-day Holter electrocardiography (ECG) monitoring. AF burden will be calculated as the total duration of AF episodes divided by the total analyzable ECG monitoring time, multiplied by 100. AF burden will be expressed as a percentage, ranging from 0% to 100%, with higher percentages indicating greater AF burden.

    Time frame: 1year

  17. Change From Baseline to 1 Year in Atrial Fibrillation-Related Quality of Life Assessed by the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT)

    Atrial fibrillation (AF)-related quality of life will be assessed using the Atrial Fibrillation Effect on QualiTy-of-Life Questionnaire (AFEQT) at baseline and 1 year. The AFEQT overall score ranges from 0 to 100, with higher scores indicating better AF-related quality of life. Change from baseline will be calculated as the score at 1 year minus the baseline score. A positive change indicates an improvement in AF-related quality of life.

    Time frame: Baseline and 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):15-25. doi: 10.1161/CIRCEP.110.958033. Epub 2010 Dec 15. PubMed 21160035 ↗
  • Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19. PubMed 24251359 ↗
  • Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10. PubMed 21830957 ↗
  • Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. Epub 2010 Mar 15. PubMed 20231232 ↗
  • Lange S, Freitag G. Choice of delta: requirements and reality--results of a systematic review. Biom J. 2005 Feb;47(1):12-27; discussion 99-107. doi: 10.1002/bimj.200410085. PubMed 16395993 ↗
  • Jeong JH, Baek YS, Park J, Park HW, Choi EK, Park JK, Kang KW, Kim J, Lee YS, Kim JB, Choi JI, Joung B, Shim J. Impact of Atrial Fibrillation with Rapid Ventricular Response on Atrial Fibrillation Recurrence: From the CODE-AF Registry. J Clin Med. 2024 Sep 14;13(18):5469. doi: 10.3390/jcm13185469. PubMed 39336961 ↗
  • Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Macle L, Verma A; EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021 Jan 28;384(4):305-315. doi: 10.1056/NEJMoa2029980. Epub 2020 Nov 16. PubMed 33197159 ↗
  • Bhat A, Khanna S, Chen HHL, Gan GCH, MacIntyre CR, Tan TC. Drivers of hospitalization in atrial fibrillation: A contemporary review. Heart Rhythm. 2020 Nov;17(11):1991-1999. doi: 10.1016/j.hrthm.2020.06.015. Epub 2020 Jun 19. PubMed 32565194 ↗
  • Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, Rosenberg YD, Jeffries N, Mitchell LB, Flaker GC, Pokushalov E, Romanov A, Bunch TJ, Noelker G, Ardashev A, Revishvili A, Wilber DJ, Cappato R, Kuck KH, Hindricks G, Davies DW, Kowey PR, Naccarelli GV, Reiffel JA, Piccini JP, Silverstein AP, Al-Khalidi HR, Lee KL; CABANA Investigators. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019 Apr 2;321(13):1261-1274. doi: 10.1001/jama.2019.0693. PubMed 30874766 ↗
  • Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, Kim TH, Pak HN, Lee MH, Lip GYH, Joung B. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ. 2021 May 11;373:n991. doi: 10.1136/bmj.n991. PubMed 33975876 ↗
  • Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29. PubMed 32865375 ↗
  • Lim J, Lee MS, Suh JH, Kang S, Lee HS, Jang JH, Son JM, Kwon JM, Kim YJ, Kim KH, Lee SP. Artificial Intelligence-Enabled ECG for Elevated E/e' on Echocardiography: Hemodynamic Relevance and Prognostic Value. J Am Heart Assoc. 2026 May 5;15(9):e046989. doi: 10.1161/JAHA.125.046989. Epub 2026 Apr 28. PubMed 42047199 ↗
  • Jeong JH, Kang S, Lee HS, Lee MS, Son JM, Kwon JM, Lee HS, Choi YY, Kim SR, Cho DH, Kim YG, Kim MN, Shim J, Park SM, Kim YH, Choi JI. Deep learning algorithm for predicting left ventricular systolic dysfunction in atrial fibrillation with rapid ventricular response. Eur Heart J Digit Health. 2024 Aug 19;5(6):683-691. doi: 10.1093/ehjdh/ztae062. eCollection 2024 Nov. PubMed 39563911 ↗
  • Kwon JM, Jo YY, Lee SY, Kang S, Lim SY, Lee MS, Kim KH. Artificial Intelligence-Enhanced Smartwatch ECG for Heart Failure-Reduced Ejection Fraction Detection by Generating 12-Lead ECG. Diagnostics (Basel). 2022 Mar 8;12(3):654. doi: 10.3390/diagnostics12030654. PubMed 35328207 ↗
  • Kwon JM, Kim KH, Jeon KH, Kim HM, Kim MJ, Lim SM, Song PS, Park J, Choi RK, Oh BH. Development and Validation of Deep-Learning Algorithm for Electrocardiography-Based Heart Failure Identification. Korean Circ J. 2019 Jul;49(7):629-639. doi: 10.4070/kcj.2018.0446. Epub 2019 Mar 21. PubMed 31074221 ↗
  • Rahimi AR, York M, Gheewala N, Markson L, Hauser TH, Manning WJ. Trends in outpatient transthoracic echocardiography: impact of appropriateness criteria publication. Am J Med. 2011 Aug;124(8):740-6. doi: 10.1016/j.amjmed.2011.03.030. PubMed 21787903 ↗
  • Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR; Peer Review Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30. PubMed 38033089 ↗
  • Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, De Potter TJR, Dwight J, Guasti L, Hanke T, Jaarsma T, Lettino M, Lochen ML, Lumbers RT, Maesen B, Molgaard I, Rosano GMC, Sanders P, Schnabel RB, Suwalski P, Svennberg E, Tamargo J, Tica O, Traykov V, Tzeis S, Kotecha D; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176. No abstract available. PubMed 39210723 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.

Of 795 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,050 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2029
CompletionEst.
Jun 1, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938281
Responsible party
Jong-Il Choi (Prof., Korea University Anam Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2029 (estimated)
Completion
Jun 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Jong IL Choi, Ph.D
Contact
stabler92@gmail.com
82-10-2122-5476
Eunjin Ahn
Contact
chloe.ahn@trinitycro.com
82-10-2540-4608

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion